We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mouse Genome Helps Identify Cancer Genes

By Biotechdaily staff writers
Posted on 13 Aug 2002
Researchers have identified a group of 21 potential cancer genes that collaborate in the absence of the tumor-suppressing protein p27 in the transformation of normal cells into cancer cells. More...
Their work was published in the July 31, 2002, online issue of the Proceedings of the National Academy of Sciences.

"We focused on the p27 pathway because the protein has been implicated in the development of many cancers,” said Dr. Bruce E. Clurman, a researcher at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA; www.fhcrc.org). "In normal cells, the p27 protein blocks cells division in response to many signals and p27 functions as a tumor suppressor. That is, the loss of p27 function is associated with the development of cancer. But how p27 works to suppress cancer is unknown.”

The researchers infected groups of both normal and p27-deficient mice with Moloney leukemia virus, which causes lymphomas in mice. They then used genome sequence information to determine the identities of the mouse genes adjacent to sites of viral insertion. Although tumors formed in both groups of mice, the process was greatly accelerated in the p27-deficient animals.

Two common insertion sites were identified. Each insertion occurred in seven different p27-deficient animals, but only rarely in the normal mice. One insertion was near a gene called Jundp2, which forms a protein known to interact with another cancer-causing gene called Jun. Jundp2 was not previously known to be carcinogenic. The other insertion was in a region of the X chromosome of the mouse, where genes have not yet been well characterized.

"Figuring out the identity of the genes near insertion sites was greatly facilitated by the recent completion of the mouse genome sequence,” Dr. Clurman said. "The technique of insertional mutagenesis with the Moloney virus, combined with the resources of human and mouse genome sequences, allows one to start with one defined mutation--in our case, p27--and identify an enormous number of genes involved in cancer.”


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.